Evidence map›Paper›PMID 40151126›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025

Mechanism of Qigu capsule as a treatment for sarcopenia based on network pharmacology and experimental validation.

Shi Jinyu, Pan Fuwei, G E Haiya, Yang Zongrui, Zhan Hongsheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shi JinyuShi's Center of Orthopedics and Traumatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200120, China.
Pan FuweiShi's Center of Orthopedics and Traumatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200120, China.
G E HaiyaShi's Center of Orthopedics and Traumatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200120, China.
Yang ZongruiShi's Center of Orthopedics and Traumatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200120, China.
Zhan HongshengShi's Center of Orthopedics and Traumatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200120, China.

Funding

Program for Shanghai High-Level Local University Innovation Team SZY20220315Shanghai Clinical Research Center for Chronic Musculoskeletal Diseases 20MC1920600Shanghai High-level Local Universities "Chronic Muscle and Bone Damage Research and Transformation" Innovation Team [No. 3 of Shanghai Education Commission (2022)] No. 3 of Shanghai Education Commission (2022)Shanghai Key Clinical Specialty "Traditional Chinese Medicine Orthopaedic Traumatology" shslczdzk03901Shanghai Shenkang Hospital Development Center Clinical Three-year Action Plan SHDC2020CR3090BThe Second Round of Construction Project of National TCM Academic School Inheritance Studio "Shi's Trauma Department" Letter of the People's Education of Traditional Chinese Medicine (2019) No. 62
6 · The paper itself

Abstract

objectiveTo explore the potential molecular mechanism of Qigu capsule (，QGC) in the treatment of sarcopenia through network pharmacology and to verify it experimentally.

methodsThe active compounds of QGC and common targets between QGC and sarcopenia were screened from databases. Then the herbs-compounds-targets network, and protein-protein interaction (PPI) network was constructed. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed by R software. Next, we used a dexamethasone-induced sarcopenia mouse model to evaluate the anti-sarcopenic mechanism of QGC.

resultsA total of 57 common targets of QGC and sarcopenia were obtained. Based on the enrichment analysis of GO and KEGG, we took the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway as a key target to explore the mechanism of QGC on sarcopenia. Animal experiments showed that QGC could increase muscle strength and inhibit muscle fiber atrophy. In the model group, the expression of muscle ring finger-1 and Atrogin-1 were increased, while myosin heavy chain was decreased, QGC treatment reversed these changes. Moreover, compared with the model group, the expressions of p-PI3K, p-Akt, p-mammalian target of rapamycin and p-Forkhead box O3 in the QGC group were all upregulated.

conclusionQGC exerts an anti-sarcopenic effect by activating PI3K/Akt signaling pathway to regulate skeletal muscle protein metabolism.

Indexed as

Drugs, Chinese HerbalSarcopeniaAnimalsCapsulesHumansMaleMiceMuscle ProteinsNetwork PharmacologyPhosphatidylinositol 3-KinasesProtein Interaction MapsProto-Oncogene Proteins c-aktSignal TransductionCapsulesDrugs, Chinese HerbalMuscle ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktexperimental validationNetwork pharmacologyphosphatidylinositol 3-kinaseproto-oncogene proteins c-aktQigu capsulesarcopeniasignal transduction

Identifiers

PMID40151126
PMCPMC11955765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.